QT time prolongation
Adverse drug events
Variants ✨For the computationally intensive evaluation of the variants, please choose the paid standard subscription.
Loprazolam is used in some countries for the short-term treatment of severe sleep disorders. It is given orally as a tablet. Loprazolam is a representative of the benzodiazepines. Like all benzodiazepines, it increases the activity of the messenger substance GABA in the brain by binding to the corresponding receptor. GABA (gamma-aminobutyric acid) is a dampening messenger substance, depending on the concentration it causes calmness or sleep, reduces anxiety and has an antispasmodic and muscle-relaxing effect. Due to the side effects, the risk of falling is increased. Already after a short time it can lead to habituation or dependence, which is why the application should be as short as possible.
The warnings are checked for the combination of several active substances. For the individual substances, please consult the relevant specialist information.
Since only loprazolam was entered without any further substances, no pharmacokinetic interaction can be detected.
The pharmacokinetic parameters of the average population are used as the starting point for calculating the individual changes in exposure due to the interactions.
The bioavailability of loprazolam is unknown. The terminal half-life [ t12 ] is 9 hours and constant plasma levels [ Css ] are reached after approximately 36 hours. Protein binding [ Pb ] is not known. The metabolism via cytochromes is currently still being worked on.
|Serotonergic Effects a||0||Ø|
Rating: According to our knowledge, loprazolam does not increase serotonergic activity.
|Kiesel & Durán b||0||Ø|
Rating: According to our knowledge, loprazolam does not increase anticholinergic activity.
QT time prolongation
We do not know of any QT-prolonging potential for loprazolam.
General adverse effects
|Side effects||∑ frequency||lop|
|Mood changes||1.0 %||+|
|Respiratory depression||0.0 %||0.0|
Based on your answers and scientific information, we assess the individual risk of undesirable side effects. These recommendations are intended to advise professionals and are not a substitute for consultation with a doctor. In the restricted test version (alpha), the risk of all substances has not yet been conclusively assessed.
No literature information available.